Spectrum of Mutations in BRCA1, BRCA2, CHEK2, and TP53 in Families at High Risk of Breast Cancer
The DOI matches its Crossref record; 61 of the 61 references it cites were found in a registry or an index.
Abstract
CONTEXT: Genetic testing for inherited mutations in BRCA1 and BRCA2 has become integral to the care of women with a severe family history of breast or ovarian cancer, but an unknown number of patients receive negative (ie, wild-type) results when they actually carry a pathogenic BRCA1 or BRCA2 mutation. Furthermore, other breast cancer genes generally are not evaluated. OBJECTIVE: To determine the frequency and types of undetected cancer-predisposing mutations in BRCA1, BRCA2, CHEK2, TP53, and PTEN among patients with breast cancer from high-risk families with negative (wild-type) genetic test results for BRCA1 and BRCA2. DESIGN, SETTING, AND PARTICIPANTS: Between 2002-2005, probands from 300 US families with 4 or more cases of breast or ovarian cancer but with negative (wild-type) commercial genetic test results for BRCA1 and BRCA2 were screened by multiple DNA-based and RNA-based methods to detect genomic rearrangements in BRCA1 and BRCA2 and germline mutations of all classes in CHEK2, TP53, and PTEN. MAIN OUTCOME MEASURES: Previously undetected germline mutations in BRCA1, BRCA2, CHEK2, TP53, and PTEN that predispose to breast cancer; frequencies of these mutations among families with negative genetic test results. RESULTS: Of the 300 probands, 52 (17%) carried previously undetected mutations, including 35 (12%) with genomic rearrangements of BRCA1 or BRCA2, 14 (5%) with CHEK2 mutations, and 3 (1%) with TP53 mutations. At BRCA1 and BRCA2, 22 different genomic rearrangements were found, of sizes less than 1 kb to greater than 170 kb; of these, 14 were not previously described and all were individually rare. At CHEK2, a novel 5.6-kb genomic deletion was discovered in 2 families of Czechoslovakian ancestry. This deletion was found in 8 of 631 (1.3%) patients with breast cancer and in none of 367 healthy controls in the Czech and Slovak Republics. For all rearrangements, exact genomic breakpoints were determined and diagnostic primers validated. The 3 families with TP53 mutations included cases of childhood sarcoma or brain tumors in addition to multiple cases of breast cancer. CONCLUSIONS: The mutational spectra of BRCA1 and BRCA2 include many high-penetrance, individually rare genomic rearrangements. Among patients with breast cancer and severe family histories of cancer who test negative (wild type) for BRCA1 and BRCA2, approximately 12% can be expected to carry a large genomic deletion or duplication in one of these genes, and approximately 5% can be expected to carry a mutation in CHEK2 or TP53. Effective methods for identifying these mutations should be made available to women at high risk.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Breast and Ovarian Cancer Risks Due to Inherited Mutations in BRCA1 and BRCA2
King, M.-C., Marks, J. H., & Mandell, J. B. (2003) · Science · doi:10.1126/science.1088759 · Cited by 2,229
Self-citationESEfinder: a web resource to identify exonic splicing enhancers
Cartegni, L. (2003) · Nucleic Acids Research · doi:10.1093/nar/gkg616 · Cited by 1,603
Soft-Tissue Sarcomas, Breast Cancer, and Other Neoplasms: A Familial Syndrome?
LI, F. P., & FRAUMENI, J. F. (1969) · Annals of Internal Medicine · doi:10.7326/0003-4819-71-4-747 · Cited by 1,509
Prophylactic Oophorectomy in Carriers of BRCA1 or BRCA2 Mutations
Rebbeck, T. R., Lynch, H. T., Neuhausen, S. L., Narod, S. A., van't Veer, L., Garber, J. E., Evans, G., Isaacs, C., Daly, M. B., Matloff, E., et al. (2002) · New England Journal of Medicine · doi:10.1056/nejmoa012158 · Cited by 1,465
Risk-Reducing Salpingo-oophorectomy in Women with a BRCA1 or BRCA2 Mutation
Kauff, N. D., Satagopan, J. M., Robson, M. E., Scheuer, L., Hensley, M., Hudis, C. A., Ellis, N. A., Boyd, J., Borgen, P. I., Barakat, R. R., et al. (2002) · New England Journal of Medicine · doi:10.1056/nejmoa020119 · Cited by 1,251
The CHEK2-Breast Cancer Consortium (2002) · Nature Genetics · doi:10.1038/ng879 · Cited by 1,104 · cited 3×
“In contrast, inherited mutations in CHEK2 are less severe, leading to an approximately 2-fold increase in risk of breast cancer.(11-13) Previous evidence suggested that mutations in CHEK2 also increase risk for prostate and thyroid cancers.”
BackgroundRisch, H. A., McLaughlin, J. R., Cole, D. E. C., Rosen, B., Bradley, L., Kwan, E., Jack, E., Vesprini, D. J., Kuperstein, G., Abrahamson, J. L. A., et al. (2001) · The American Journal of Human Genetics · doi:10.1086/318787 · Cited by 986
Breast Cancer after Prophylactic Bilateral Mastectomy in Women with a BRCA1 or BRCA2 Mutation
Meijers-Heijboer, H., van Geel, B., van Putten, W. L. J., Henzen-Logmans, S. C., Seynaeve, C., Menke-Pluymers, M. B. E., Bartels, C. C. M., Verhoog, L. C., van den Ouweland, A. M. W., Niermeijer, M. F., et al. (2001) · New England Journal of Medicine · doi:10.1056/nejm200107193450301 · Cited by 973 · cited 3×
“Clinical options for women at high genetic risk of breast cancer include screening starting at a young age,(19) the use of highly sensitive detection methods,(20) and prophylactic surgeries of the ovaries or breast.(21-27) Because prophylactic surgeries, while highly effective in reducing risk, are also highly invasiv…”
BackgroundBurke, W. (1997) · JAMA · doi:10.1001/jama.277.12.997 · Cited by 955
Prevalence of BRCA1 and BRCA2 Gene Mutations in Patients With Early-Onset Breast Cancer
Peto, J., Collins, N., Barfoot, R., Seal, S., Warren, W., Rahman, N., Easton, D. F., Evans, C., Deacon, J., & Stratton, M. R. (1999) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/91.11.943 · Cited by 873
King, M.-C. (2001) · JAMA · doi:10.1001/jama.286.18.2251 · Cited by 776
Self-citationEfficacy of Bilateral Prophylactic Mastectomy in BRCA1 and BRCA2 Gene Mutation Carriers
Hartmann, L. C., Sellers, T. A., Schaid, D. J., Frank, T. S., Soderberg, C. L., Sitta, D. L., Frost, M. H., Grant, C. S., Donohue, J. H., Woods, J. E., et al. (2001) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/93.21.1633 · Cited by 743
BRCA1 and BRCA2 mutations account for a large proportion of ovarian carcinoma cases
Pal, T., Permuth‐Wey, J., Betts, J. A., Krischer, J. P., Fiorica, J., Arango, H., LaPolla, J., Hoffman, M., Martino, M. A., Wakeley, K., et al. (2005) · Cancer · doi:10.1002/cncr.21536 · Cited by 691
Will the real Cowden syndrome please stand up: revised diagnostic criteria
Eng, C. (2000) · Journal of Medical Genetics · doi:10.1136/jmg.37.11.828 · Cited by 566
CHEK2 Is a Multiorgan Cancer Susceptibility Gene
Cybulski, C., Górski, B., Huzarski, T., Masojć, B., Mierzejewski, M., Dębniak, T., Teodorczyk, U., Byrski, T., Gronwald, J., Matyjasik, J., et al. (2004) · The American Journal of Human Genetics · doi:10.1086/426403 · Cited by 551
The Cowden syndrome: a clinical and genetic study in 21 patients
Starink, T. M., Veen, J. P. W. V. D., Arwert, F., Waal, L. P. D., Lange, G. G. D., Gille, J. J. P., & Eriksson, A. W. (1986) · Clinical Genetics · doi:10.1111/j.1399-0004.1986.tb00816.x · Cited by 550
A mechanism for exon skipping caused by nonsense or missense mutations in BRCA1 and other genes
Liu, H.-X., Cartegni, L., Zhang, M. Q., & Krainer, A. R. (2001) · Nature Genetics · doi:10.1038/83762 · Cited by 477
(2004) · The American Journal of Human Genetics · doi:10.1086/421251 · Cited by 471
Frank, T. S., Manley, S. A., Olopade, O. I., Cummings, S., Garber, J. E., Bernhardt, B., Antman, K., Russo, D., Wood, M. E., Mullineau, L., et al. (1998) · Journal of Clinical Oncology · doi:10.1200/jco.1998.16.7.2417 · Cited by 455
Eisen, A., Lubinski, J., Klijn, J., Moller, P., Lynch, H. T., Offit, K., Weber, B., Rebbeck, T., Neuhausen, S. L., Ghadirian, P., et al. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2004.00.7138 · Cited by 443
Germ-line p53 mutations predispose to a wide spectrum of early-onset cancers.
Nichols, K. E., Malkin, D. M., Garber, J. E., Fraumeni, J. F., & Li, F. P. (2001) · PubMed · Cited by 354
Nelson, H. D., Huffman, L. H., Fu, R., & Harris, E. L. (2005) · Annals of Internal Medicine · doi:10.7326/0003-4819-143-5-200509060-00012 · Cited by 346
Newman, B. (1998) · JAMA · doi:10.1001/jama.279.12.915 · Cited by 345
BRCA1 and BRCA2 Mutation Analysis of 208 Ashkenazi Jewish Women with Ovarian Cancer
Moslehi, R., Chu, W., Karlan, B., Fishman, D., Risch, H., Fields, A., Smotkin, D., Ben-David, Y., Rosenblatt, J., Russo, D., et al. (2000) · The American Journal of Human Genetics · doi:10.1086/302853 · Cited by 314
Hogervorst, F. B. L., Nederlof, P. M., Gille, J. J. P., McElgunn, C. J., Grippeling, M., Pruntel, R., Regnerus, R., van Welsem, T., van Spaendonk, R., Menko, F. H., et al. (2003) · PubMed · Cited by 314
Mutations in CHEK2 Associated with Prostate Cancer Risk
Dong, X., Wang, L., Taniguchi, K., Wang, X., Cunningham, J. M., McDonnell, S. K., Qian, C., Marks, A. F., Slager, S. L., Peterson, B. J., et al. (2003) · The American Journal of Human Genetics · doi:10.1086/346094 · Cited by 308
BRCA1 Mutations in a Population-Based Sample of Young Women with Breast Cancer
Langston, A. A., Malone, K. E., Thompson, J. D., Daling, J. R., & Ostrander, E. A. (1996) · New England Journal of Medicine · doi:10.1056/nejm199601183340301 · Cited by 286
Zhou, X.-P., Waite, K. A., Pilarski, R., Hampel, H., Fernandez, M. J., Bos, C., Dasouki, M., Feldman, G. L., Greenberg, L. A., Ivanovich, J., et al. (2003) · The American Journal of Human Genetics · doi:10.1086/377109 · Cited by 285
Lynch, E. D., Ostermeyer, E. A., Lee, M. K., Arena, J. F., Ji, H., Dann, J., Swisshelm, K., Suchard, D., MacLeod, P. M., Kvinnsland, S., et al. (1997) · The American Journal of Human Genetics · doi:10.1086/301639 · Cited by 276
Self-citationThe role of Alu repeat clusters as mediators of recurrent chromosomal aberrations in tumors
Kolomietz, E., Meyn, M. S., Pandita, A., & Squire, J. A. (2002) · Genes, Chromosomes and Cancer · doi:10.1002/gcc.10111 · Cited by 262
Outcome of Preventive Surgery and Screening for Breast and Ovarian Cancer in BRCA Mutation Carriers
Scheuer, L., Kauff, N., Robson, M., Kelly, B., Barakat, R., Satagopan, J., Ellis, N., Hensley, M., Boyd, J., Borgen, P., et al. (2002) · Journal of Clinical Oncology · doi:10.1200/jco.2002.20.5.1260 · Cited by 239
Montagna, M. (2003) · Human Molecular Genetics · doi:10.1093/hmg/ddg120 · Cited by 183
Minimal Conditions for Exonization of Intronic Sequences
Sorek, R., Lev-Maor, G., Reznik, M., Dagan, T., Belinky, F., Graur, D., & Ast, G. (2004) · Molecular Cell · doi:10.1016/s1097-2765(04)00181-9 · Cited by 170
Genomic rearrangements in theBRCA1 andBRCA2 genes
Mazoyer, S. (2005) · Human Mutation · doi:10.1002/humu.20169 · Cited by 164
CHEK2 variant I157T may be associated with increased breast cancer risk
Kilpivaara, O., Vahteristo, P., Falck, J., Syrjäkoski, K., Eerola, H., Easton, D., Bartkova, J., Lukas, J., Heikkilä, P., Aittomäki, K., et al. (2004) · International Journal of Cancer · doi:10.1002/ijc.20299 · Cited by 163
A Novel Founder CHEK2 Mutation is Associated with Increased Prostate Cancer Risk
Cybulski, C., Huzarski, T., Górski, B., Masojć, B., Mierzejewski, M., Dębniak, T., Gliniewicz, B., Trubicka, J., Złowocka, E., Kurzawski, G., et al. (2004) · Cancer Research · doi:10.1158/0008-5472.can-04-0341 · Cited by 158
Unger, M. A., Nathanson, K. L., Calzone, K., Antin-Ozerkis, D. E., Shih, H. A., Martin, A., Lenoir, G., Mazoyer, S., & Weber, B. L. (2000) · The American Journal of Human Genetics · doi:10.1086/303076 · Cited by 157
Tsou, H. C., Teng, D. H. ‐., Ping, X. L., Brancolini, V., Davis, T., Hu, R., Xie, X. X., Gruener, A. C., Schrager, C. A., Christiano, A. M., et al. (1997) · The American Journal of Human Genetics · doi:10.1086/301607 · Cited by 153
CHEK2 variants associate with hereditary prostate cancer
Seppälä, E. H., Ikonen, T., Mononen, N., Autio, V., Rökman, A., Matikainen, M. P., Tammela, T. L. J., & Schleutker, J. (2003) · British Journal of Cancer · doi:10.1038/sj.bjc.6601425 · Cited by 147
Shaag, A., Walsh, T., Renbaum, P., Kirchhoff, T., Nafa, K., Shiovitz, S., Mandell, J. B., Welcsh, P. L., Lee, M. K., Ellis, N. A., et al. (2005) · Human Molecular Genetics · doi:10.1093/hmg/ddi052 · Cited by 143
Self-citationAntoniou, A. C., Pharoah, P. D. P., Narod, S. A., Risch, H. A., Eyfjord, J. E., Hopper, J. L., Olsson, H. L., Johannsson, O. T., Borg, Å., Pasini, B., et al. (2005) · Journal of Medical Genetics · doi:10.1136/jmg.2004.024133 · Cited by 141
Schutte, M. E. M., Seal, S., Barfoot, R., Meijers-Heijboer, H. E. J., Wasielewski, M., Evans, D. G., Eccles, D., Meijers, C., Lohman, F. P., Klijn, J. G. M., et al. (2003) · The American Journal of Human Genetics · doi:10.1086/373965 · Cited by 136
Kramer, J. L., Velazquez, I. A., Chen, B. E., Rosenberg, P. S., Struewing, J. P., & Greene, M. H. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.02.9199 · Cited by 135
Breast cancer predisposing alleles in Poland
Górski, B., Cybulski, C., Huzarski, T., Byrski, T., Gronwald, J., Jakubowska, A., Stawicka, M., Grodecka-Gazdecka, S., Szwiec, M., Urbański, K., et al. (2005) · Breast Cancer Research and Treatment · doi:10.1007/s10549-005-1409-1 · Cited by 128
Oldenburg, R. A., Kroeze‐Jansema, K., Kraan, J., Morreau, H. M., Klijn, J. G. M., Hoogerbrugge, N., Ligtenberg, M. J. L., van Asperen, C. J., Vasen, H. F. A., Meijers, C., et al. (2003) · PubMed · Cited by 112
Woodward, A., Davis, T. A., Silva, A. G. S., Kirk, J. A., & Leary, J. A. (2005) · Journal of Medical Genetics · doi:10.1136/jmg.2004.027961 · Cited by 99
BRCA2 T2722R Is a Deleterious Allele That Causes Exon Skipping
Fackenthal, J. D., Cartegni, L., Krainer, A. R., & Olopade, O. I. (2002) · The American Journal of Human Genetics · doi:10.1086/342192 · Cited by 98
Susani, L., Pangrazio, A., Sobacchi, C., et al. (2004) · Human Mutation · doi:10.1002/humu.20076 · Cited by 95
Limited relevance of the CHEK2 gene in hereditary breast cancer
Dufault, M. R., Betz, B., Wappenschmidt, B., Hofmann, W., Bandick, K., Golla, A., Pietschmann, A., Nestle-Krämling, C., Rhiem, K., Hüttner, C., et al. (2004) · International Journal of Cancer · doi:10.1002/ijc.20073 · Cited by 94
Association of two mutations in the CHEK2 gene with breast cancer
Bogdanova, N. V., Enβen‐Dubrowinskaja, N., Feshchenko, S., Lazjuk, G. I., Rogov, Y., Dammann, O., Bremer, M., Karstens, J. H., Sohn, C., & Dörk, T. (2005) · International Journal of Cancer · doi:10.1002/ijc.21022 · Cited by 93
Large genomic deletions inactivate the BRCA2 gene in breast cancer families
Agata, S., Palma, M. D., Callegaro, M., Scaini, M. C., Menin, C., Ghiotto, C., Nicoletto, O., Zavagno, G., Chieco-Bianchi, L., D’Andrea, E., et al. (2005) · Journal of Medical Genetics · doi:10.1136/jmg.2005.032789 · Cited by 66
Hirsh‐Yechezkel, G., Chetrit, A., Lubin, F., Friedman, E., Peretz, T., Gershoni, R., Rizel, S., Struewing, J. P., & Modan, B. (2003) · Gynecologic Oncology · doi:10.1016/s0090-8258(03)00152-5 · Cited by 65
Rapakko, K., Allinen, M., Syrjäkoski, K., Vahteristo, P., Huusko, P., Vähäkangas, K., Eerola, H., Kainu, T., Kallioniemi, O., Nevanlinna, H. A., et al. (2001) · British Journal of Cancer · doi:10.1054/bjoc.2000.1530 · Cited by 58
Hendrickson, B. C., Judkins, T., Ward, B. D., et al. (2005) · Genes Chromosomes and Cancer · doi:10.1002/gcc.20189 · Cited by 56
Pathology of breast cancer in women with constitutional CHEK2 mutations
Huzarski, T., Cybulski, C., Domagała, W., Gronwald, J., Byrski, T., Szwiec, M., Woyke, S., Narod, S. A., & Lubiński, J. (2005) · Breast Cancer Research and Treatment · doi:10.1007/s10549-004-3778-2 · Cited by 48
Campos, B., Dı́ez, O., Domènech, M., Baena, M., Balmañà, J., Sanz, J., Ramírez, A., Alonso, C., & Baiget, M. (2003) · Human Mutation · doi:10.1002/humu.9176 · Cited by 39
MRI surveillance for hereditary breast-cancer risk
Warner, E., & Causer, P. A. (2005) · The Lancet · doi:10.1016/s0140-6736(05)66520-8 · Cited by 38
Pettigrew, C. A., Wayte, N., Lovelock, P. K., Tavtigian, S. V., Chenevix‐Trench, G., Spurdle, A. B., & Brown, M. A. (2005) · Breast Cancer Research · doi:10.1186/bcr1324 · Cited by 38
The Alu insertion in the CLCN5 gene of a patient with Dent’s disease leads to exon 11 skipping
Claveríe‐Martín, F., Flores, C., Antón-Gamero, M., González-Acosta, H., & Nieto, V. M. G. (2005) · Journal of Human Genetics · doi:10.1007/s10038-005-0265-5 · Cited by 37
A new alternative splice variant of BRCA1 containing an additional in-frame exon
Fortin, J., Moisan, A. M., Dumont, M., Leblanc, G., Labrie, Y., Durocher, F., Bessette, P., Bridge, P. J., Chiquette, J., Laframboise, R., et al. (2005) · Biochimica et Biophysica Acta (BBA) - Gene Structure and Expression · doi:10.1016/j.bbaexp.2005.08.011 · Cited by 22
AluElements: Repetitive DNA as Facilitators of Chromosomal Rearrangement.
McNeil, N. E. (2004) · PubMed · Cited by 10
Cited by
Walsh, T., Casadei, S., Lee, M. K., Pennil, C. C., Nord, A. S., Thornton, A. M., Roeb, W., Agnew, K. J., Stray, S. M., Wickramanayake, A., et al. (2011) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1115052108 · Cited by 933
Self-citationNCCN Guidelines Insights: Genetic/Familial High-Risk Assessment: Breast and Ovarian, Version 2.2017
Daly, M. B., Pilarski, R., Berry, M., Buys, S. S., Farmer, M., Friedman, S., Garber, J. E., Kauff, N. D., Khan, S., Klein, C., et al. (2017) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2017.0003 · Cited by 650
Self-citationGenetic/Familial High-Risk Assessment: Breast and Ovarian
Daly, M. B., Axilbund, J. E., Buys, S., Crawford, B., Farrell, C. D., Friedman, S., Garber, J. E., Goorha, S., Gruber, S. B., Hampel, H., et al. (2010) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2010.0043 · Cited by 646
Self-citationGenome-wide association study identifies a new breast cancer susceptibility locus at 6q25.1
Zheng, W., Long, J., Gao, Y.-T., Li, C., Zheng, Y., Xiang, Y.-B., Wen, W., Levy, S., Deming, S. L., Haines, J. L., et al. (2009) · Nature Genetics · doi:10.1038/ng.318 · Cited by 541
Genetics of breast cancer: a topic in evolution
Shiovitz, S., & Korde, L. A. (2015) · Annals of Oncology · doi:10.1093/annonc/mdv022 · Cited by 525
Metadata
- Authors
- Walsh, T., Casadei, S., Coats, K. H., Swisher, E., Stray, S. M., Higgins, J., Roach, K. C., Mandell, J., Lee, M. K., Ciernikova, S., Foretova, L., Soucek, P., & King, M.-C.
- Venue
- JAMA
- Publisher
- American Medical Association (AMA)
- Published
- 2006-03-22
- Volume
- 295
- Issue
- 12
- Pages
- 1379
- ISSN
- 0002-9955 (ISSN-L)
- 0098-7484
- OpenAlex
- W2120059431
- Cited by
- 666
- References
- 61
- FWCI
- 30.93
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.